WuXi XDC (2268 HK) Summary
Core Content
WuXi XDC, a leading contract development and manufacturing organization (CDMO) in the biopharmaceutical industry, has reported strong financial performance and strategic initiatives for 2025 and beyond. The company is expected to achieve significant revenue and net profit growth, driven by its expanding client base and the acquisition of BioDlink.
Key Financial Highlights
- Revenue Growth: WuXi XDC expects revenue to grow by 45.7% in 2025, 36.6% in 2026, and 31.7% in 2027.
- Adjusted Net Profit: Adjusted net profit is projected to increase by 34.9%, 38.4%, and 32.9% in 2025E, 2026E, and 2027E respectively.
- Earnings Per Share (EPS): Adjusted EPS is forecasted to rise to RMB 1.17, RMB 1.62, and RMB 2.15 in 2025E, 2026E, and 2027E.
- Profit Margins:
- Gross margin is expected to increase to 35.7%, 37.2%, and 38.0%.
- Operating margin is projected to reach 30.6%, 29.3%, and 29.9%.
- Adjusted net profit margin is forecasted to be 26.8%, 27.2%, and 27.4%.
Strategic Acquisition
- WuXi XDC announced a cash offer to acquire at least 60% of BioDlink (东曜药业, 1875 HK), at HK$4.00 per share, which is a 99% premium over the last closing price of BioDlink on 24 Dec 2025.
- BioDlink is a leading ADC CDMO with RMB207mn in CDMO-related revenue in 2024.
- The acquisition aims to enhance production capacity, especially for ADC DS and DP, which are currently in short supply.
- BioDlink operates:
- 2 mAb facilities (500-2,000L/batch)
- 3 DS facilities (over 800kg ADC DS annually)
- 3 DP facilities (over 8 million vials annually)
Project Growth
- In 2025, WuXi XDC signed 70 new integrated projects, a 32% increase YoY.
- PPQ projects surged by 125% YoY to 18, indicating strong potential for commercial manufacturing.
- Novel modalities made up a significant portion of the new projects:
- Bispecific ADCs: ~20%
- Dual-payload ADCs: ~5%
- Other novel XDCs: ~17%
Future Revenue Projections
- By 2030, 20% of WuXi XDC's revenue is expected to come from novel XDC projects, and another 20% from commercial-stage projects.
Valuation and Investment Recommendation
- Target Price: Raised to HK$88.00, up from HK$74.00, reflecting enhanced global competitiveness and positive demand outlook.
- Up/Downside: 20.7%.
- Current Price: HK$72.90.
- DCF Valuation: HK$99.417bn (equity value).
- P/E (Adjusted): 56.2x, 40.6x, and 30.5x for 2025E, 2026E, and 2027E respectively.
Shareholding and Stock Performance
- Shareholding Structure:
- WuXi Biologics: 50.7%
- WuXi AppTec: 18.6%
- Market Cap: HK$87,366.6 million
- Stock Performance:
- 1-month: 6.0%
- 3-month: 4.7%
- 6-month: 49.5%
Financial Summary
| Metric |
2025E (RMB mn) |
2026E (RMB mn) |
2027E (RMB mn) |
| Revenue |
5,906 |
8,065 |
10,619 |
| Gross Profit |
2,107 |
2,998 |
4,032 |
| Operating Profit |
1,806 |
2,359 |
3,172 |
| Non-IFRS Net Profit |
1,584 |
2,192 |
2,914 |
| Net Profit (RMB) |
1,486 |
2,075 |
2,766 |
| Net Debt to Equity (x) |
0.5 |
0.5 |
0.5 |
| Current Ratio (x) |
3.1 |
2.9 |
2.9 |
Valuation Metrics
| Metric |
2025E |
2026E |
2027E |
| P/E (Adjusted) |
56.2 |
40.6 |
30.5 |
| P/B |
7.7 |
6.4 |
5.2 |
| P/CFPS |
51.7 |
37.0 |
27.3 |
Analyst Recommendation
- Maintain BUY: Reflecting the company's strong growth prospects and strategic moves.
Risk Adjusted DCF Valuation
| Year |
EBIT (RMB mn) |
EBIT*(1-tax rate) (RMB mn) |
+ D&A (RMB mn) |
- Change in Working Capital (RMB mn) |
- Capex (RMB mn) |
FCFF (RMB mn) |
| 2025E |
1,614 |
1,388 |
172 |
-27 |
-1,220 |
313 |
| 2026E |
2,459 |
2,077 |
235 |
-219 |
-1,700 |
394 |
| 2027E |
3,272 |
2,764 |
309 |
-222 |
-1,800 |
1,051 |
Sensitivity Analysis
| Terminal Growth Rate |
DCF Valuation (HK$bn) |
| 3.00% |
119.91 |
| 2.50% |
112.09 |
| 2.00% |
105.44 |
| 1.50% |
99.72 |
| 1.00% |
94.75 |
Analyst Certification
- The research analyst certifies that the views expressed accurately reflect their personal views.
- No part of their compensation is directly or indirectly related to the specific views in the report.
- They have not dealt in or traded in the stock covered in this report within 30 days prior to the report's issue.
CMBIG Ratings
- BUY: Stock with potential return of over 15% over next 12 months.
- HOLD: Stock with potential return of +15% to -10% over next 12 months.
- SELL: Stock with potential loss of over 10% over next 12 months.
- NOT RATED: Stock not rated by CMBIGM.
- OUTPERFORM: Industry expected to outperform the relevant broad market benchmark.
- MARKET-PERFORM: Industry expected to perform in-line with the relevant broad market benchmark.
- UNDERPERFORM: Industry expected to underperform the relevant broad market benchmark.
Important Disclosures
- The report is for information purposes only and should not be construed as an offer or solicitation to buy or sell any security.
- CMBIGM does not provide individually tailored investment advice.
- The value of investments is uncertain and may fluctuate due to market factors.
- The report is subject to change without notice.
- CMBIGM may have conflicts of interest and does not assume responsibility for the report's objectivity.
Legal and Distribution Notes
- The report is distributed solely to major US institutional investors.
- In the UK, it is provided only to persons within Article 19(5) or Article 49(2)(a) to (d) of the Financial Promotion Order.
- In Singapore, it is distributed by CMBI, and may not be provided to any other person without prior written consent.
